139 related articles for article (PubMed ID: 11438818)
41. [Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].
Krejcí M; Hájek R; Scudla V; Bacovský J; Indrák K; Faber E; Koza V; Schützová M; Kuca B; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Rezek Z; Praskac P; Cahová S; Vránová M; Veprek K; Januska J; Kessler P; Pozdĕnová V; Walterová L; Stefánek I; Hausdorf P; Meluzínová I; Novosadová L; Lenícková S; Dusek L; Syobodník A; Králová E; Adam Z; Mayer J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():40-7. PubMed ID: 11693062
[TBL] [Abstract][Full Text] [Related]
42. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
43. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
[TBL] [Abstract][Full Text] [Related]
44. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure.
Rebibou JM; Caillot D; Casasnovas RO; Tanter Y; Maillard N; Solary E; Rifle G; Guy H
Bone Marrow Transplant; 1997 Jul; 20(1):63-5. PubMed ID: 9232259
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
46. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
47. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
[TBL] [Abstract][Full Text] [Related]
48. [The outcome analysis of different treatment regimens in 206 patients with multiple myeloma].
Mai YJ; Li R; Zou DH; Wang YF; Zhao YZ; Yang RC; Wang JX; Xiao ZJ; Han MZ; Qian LS; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Apr; 26(4):193-6. PubMed ID: 15949257
[TBL] [Abstract][Full Text] [Related]
49. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
[TBL] [Abstract][Full Text] [Related]
50. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
[TBL] [Abstract][Full Text] [Related]
51. Myeloablative therapy for primary resistant multiple myeloma.
Alexanian R; Dimopoulos MA; Delasalle KB; Hester J; Champlin R
Stem Cells; 1995 Aug; 13 Suppl 2():118-21. PubMed ID: 8520499
[TBL] [Abstract][Full Text] [Related]
52. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
[TBL] [Abstract][Full Text] [Related]
53. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
54. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
55. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
56. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
57. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
[TBL] [Abstract][Full Text] [Related]
58. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
[TBL] [Abstract][Full Text] [Related]
59. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
[TBL] [Abstract][Full Text] [Related]
60. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?
Powles R; Sirohi B; Kulkarni S; Treleaven J; Rudin C; Sankpal S; Goyal S; Horton C; Millar B; Saso R; Singhal S; Mehta J
Bone Marrow Transplant; 2002 Oct; 30(8):479-84. PubMed ID: 12379885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
